Banked, tested cell lines of Indian marine fish for cultivated-seafood labs
TL;DR Fishcellbank builds and banks food-grade cell lines from Indian marine fish such as pomfret, seer fish and grouper, then licenses them to cultivated-seafood developers. Aquaculture disease and toxicology labs, which already buy fish cells, provide early revenue. It sells the picks and shovels, not the fish.
India eats far more fish than it used to, and consumption rose 88% in just over a decade[1]. Prized marine species like pomfret and seer fish come from wild catch, so growing their meat from cells has obvious appeal. But every cultivated-seafood effort starts with the same slow step - a stable, well-characterised cell line for the species.
And those lines are scarce. Of more than 104,000 cell lines catalogued worldwide, only 883 came from fish, and permanent fish muscle lines remain rare[2]. Building one takes patience. A mackerel muscle line needed more than a year and over 130 passages before it stabilised[3]. There are also no harmonised rules for qualifying a line as food-safe, so developers test inconsistently[4].
What it does, in regulatory terms: a research-materials and laboratory-services business. Fishcellbank sells no food. Any cultivated seafood made from its lines would need FSSAI approval as a non-specified food, which no one in India has received yet[1].
The company takes tissue from a small number of fish species, isolates muscle and fat precursor cells, and works to establish stable lines without genetic modification. Each line gets a master cell bank with identity, sterility, virus and genetic-stability records, so a buyer can drop it into a regulatory dossier. Licences cover research use first, with a separate commercial licence later.
We reframed the seed, which pitched cultivated seafood as a product. In India that product is a long way off, and a CMFRI scientist expects it may take a decade to reach the market[1]. The cell line is the part worth building now, and it serves labs that already pay for fish cells today.
Early buyers are labs that use fish cell lines to grow aquaculture viruses, test vaccines or screen chemicals[2], like ICAR institutes, universities, and feed and animal-health companies. Later buyers are cultivated-seafood developers in India and abroad who want tropical species. Pricing is a per-vial research fee plus licence and milestone fees for commercial use. We found no public price list for fish lines, so you'll set yours during validation.
The National Academy of Agricultural Sciences published a 2025 policy paper on cellular fish meat, and the Department of Biotechnology has put "smart proteins" in its BioE3 policy[5]. CMFRI signed a research agreement with a cultivated-meat startup in 2024 to develop cultivated pomfret, seer fish and kingfish[1]. Public research money and partner institutes now exist for this work.
No public figure exists for fish cell line sales or licensing in India or elsewhere. The narrowest real marker of demand is India's national fish cell line repository at ICAR-NBFGR, which holds more than 50 lines from 24 species and serves as a referral centre[2]. For adjacent context (not your market), India's seafood exports reached 1.7 million tonnes worth $8.09B in 2022-23[1].
CMFRI runs early cell line work for its startup project[1], and NBFGR banks fish lines for research[2]. Both are public institutes, not commercial suppliers with food-grade documentation. One Singapore startup develops cultivated seafood for threatened species and offers its platform to seafood producers[6]. The gap is a commercial bank of documented lines from Indian Ocean species.
| Difficulty | Hard (61/100) |
| Starting capital | ₹3–6 Cr |
| Time to launch | 18–24 months |
The science is the hard part. Many fish cultures never immortalise, and each species is its own project. Food-grade testing adds cost per line, and one contaminated flask can wipe out months of passages, which is as painful as it sounds. Selling is also slow, because the main future buyers are early-stage companies with small budgets.
No food licence, because Fishcellbank sells cells and lab services, not food. Biodiversity law is the rule to watch.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't trust AI to declare a line stable, sterile or food-safe. Only real lab tests can do that.
Want to work out the AI layer for Fishcellbank? Talk to Yash →
I think this suits a cell biologist with fish or stem-cell experience and a partner institute, funded partly by grants. If you're hoping to sell seafood soon then look elsewhere. Before raising money, prove you can get one marine species past 50 passages with a stable karyotype, and sign two paying research-use customers.
Plan for roughly ₹3–6 Cr over 18–24 months, mostly lab setup, scientists, food-grade testing and the time it takes a line to stabilise.
No food licence, since you sell research materials. You do need to follow the Biological Diversity Act for commercial use of Indian species, and biosafety rules if any line is modified.
Yes. The model works anywhere with fish species that labs want. Check your local biodiversity, biosafety and export rules before you collect tissue.
The free Fishcellbank validation kit has the line-by-line capital breakdown, the effort scoring, the biosafety and biodiversity-law checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for labs and developers, and 5 assumptions to test. Download the kit →
Thinking about building Fishcellbank or something close to it? The make-or-break work is stabilising the first marine line and finding buyers before the cultivated-seafood market matures, and I can help you plan the funding around that gap. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.